Article

PRBC-derived plasma induces non-muscle myosin type IIA-mediated neutrophil migration and morphologic change

Department of Nephrology, Tongji Hospital, Tongji Universith School of Medicine , Shanghai , China.
Immunopharmacology and Immunotoxicology (Impact Factor: 1.11). 10/2012; 35(1). DOI: 10.3109/08923973.2012.677046
Source: PubMed

ABSTRACT Context: Neutrophils are the primary effector cells in the pathogenesis of transfusion-related acute lung injury or multiple organ failure after blood transfusion. Objective: We aimed to investigate the effect of fresh (1 day preparation) and aged (42 day preparation) PRBC-derived plasma on neutrophil morphology, migration and phagocytosis. Materials and methods: We evaluated the production of reactive oxygen species (ROS) and the expression of non-muscle myosin heavy chain IIA (MYH9) in neutrophils treated with PRBC-derived plasma. We used western blots and antibody arrays to evaluate changes in signal transduction pathways in plasma-treated neutrophils. Results: Aged PRBC-derived plasma elicited a stronger oxidative burst in neutrophils when compared with fresh PRBC-derived plasma (p < 0.05). Antibody arrays showed increased phosphorylation of NF-ĸB proteins (p105, p50 and Ikk) in aged PRBC-derived plasma-treated neutrophils. The expression of non-muscle myosin IIA (MYH9), a cytoskeleton protein involved in immune cell migration and morphological change, was also significantly upregulated in neutrophils treated with aged PRBC-derived plasma compared to fresh plasma (p < 0.05). Pretreatment of neutrophils with blebbistatin (a specific type II myosin inhibitor), ascorbic acid (an antioxidant), or staurosporine (a protein tyrosine kinase inhibitor), effectively abrogated the morphological changes, neutrophil migration, and phagocytosis induced by aged PRBC-derived plasma. Conclusion: Upregulation of MYH9 in neutrophils treated with aged PRBC-derived plasma and abrogation of neutrophil migration in blebbistatin-treated neutrophils suggested a functional role of MYH9 in the directional migration of immune cells. Our data help elucidate the cellular and molecular mechanisms of transfusion-related injury.

Download full-text

Full-text

Available from: Yingjie Guan, Sep 23, 2014
1 Follower
 · 
153 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The contribution of RBC transfusion to adverse patient outcomes is controversial. There is conflicting clinical data and limited biologic data that provide an underpinning biologic rationale for any adverse impacts from RBC transfusion. This study used in-vitro measures of PMN stimulation to determine the ability of supernatant from RBCs to stimulate allogeneic WBCs and to determine the influence of residual donor WBCs and storage time on the proinflammatory potential of RBCs. Three types of RBCs were assessed: standard non-WBC-reduced RBCs (S-RBCs), buffy coat-poor RBCs (BCP-RBCs), and prestorage WBC-filtered RBC (LF-RBCs). Supernatant was collected weekly up to Day 42 of storage. PMN priming by supernatant from RBCs was determined by three methods: induction of CD11b expression on PMNs, induction of IL-8 release from PMNs, and the chemotactic effect of supernatant on PMNs. Supernatant from S-RBCs induced the expression of CD11b on PMNs, primed PMNs to release IL-8, and was chemotactic for PMNs. The magnitude of this PMN-priming progressively amplified with storage time. In contrast, supernatant from BCP-RBCs or LF-RBCs did not significantly prime PMNs. The PMN-priming effect of supernatant from RBCs correlated more closely with the level of MNCs in the RBCs than PMN content. Supernatant from stored S-RBCs prime unstimulated allogeneic PMNs in vitro. Prestorage buffy-coat WBC reduction was as effective as WBC depletion in abrogating this proinflammatory response elicited by supernatants from RBCs. The clinical consequences, if any, of these findings for transfusion recipients are unknown.
    Transfusion 06/2004; 44(5):722-30. DOI:10.1111/j.1537-2995.2004.03113.x · 3.57 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Delayed apoptosis of primed neutrophils (PMNs) may facilitate PMN-mediated tissue injury leading to postinjury multiple organ failure. Aged (42-day-old) stored red blood cells (RBC42) delay PMN apoptosis through proinflammatory phospholipids such as platelet-activating factor (PAF) and lyso-phosphatidylcholine (LPC). Hypertonic saline (HTS) attenuates PMN cytotoxic functions. We hypothesized that clinically relevant HTS would provoke PMN apoptosis, as well as prevent stored blood- and lipid-mediated delayed PMN apoptosis through activation of p38 mitogen-activated protein kinase (MAPK) and caspase-3. PMNs harvested from healthy volunteers were incubated (5% CO(2), 37 degrees C, 24 hr) with RBC42 plasma, PAF (20 microM), or LPC (4.5 microM), with or without the p38 MAPK inhibitor SB 203580, the caspase-3 inhibitor zDEVD-fmk (10 micromol/L) or the pan-caspase inhibitor zVAD-fmk (20 micromol/L). Duplicate samples were preincubated in HTS (Na [180 mM]). Apoptotic index (% PMNs undergoing apoptosis) was assessed morphologically. p38 MAPK activation was assessed by Western blotting. Caspase-3 activity was measured colorimetrically. PAF, LPC, and RBC42 plasma delayed apoptosis; HTS increased apoptosis compared with controls. HTS prevented PAF, LPC, and RBC42-delayed apoptosis. p38 MAPK was not activated by HTS; its inhibition had no effect on the actions of HTS. Caspase inhibition attenuated the ability of HTS to increase apoptosis, but it did not affect the ability of HTS to restore healthy PMN apoptosis in the presence of RBC42. HTS increases PMN apoptosis and prevents stored blood- and lipid-mediated delayed PMN apoptosis. HTS may activate caspase-3, but alternative signaling pathways appear to be involved in modulating the effects of lipids on PMN apoptosis.
    Surgery 08/2003; 134(1):86-91. DOI:10.1067/msy.2003.178 · 3.11 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: How T cells achieve rapid chemotactic motility under certain circumstances and efficient cell surface surveillance in others is not fully understood. We show that T lymphocytes are motile in two distinct modes: a fast "amoeboid-like" mode, which uses sequential discontinuous contacts to the substrate; and a slower mode using a single continuously translating adhesion, similar to mesenchymal motility. Myosin-IIA is necessary for fast amoeboid motility, and our data suggests that this occurs via cyclical rear-mediated compressions that eliminate existing adhesions while licensing subsequent ones at the front of the cell. Regulation of Myosin-IIA function in T cells is thus a key mechanism to regulate surface contact area and crawling velocity within different environments. This can provide T lymphocytes with motile and adhesive properties that are uniquely suited toward alternative requirements for immune surveillance and response.
    The Journal of Immunology 03/2009; 182(4):2041-50. DOI:10.4049/jimmunol.0803267 · 5.36 Impact Factor